Updates in the Treatment of Hepatitis C Kelsey Palmer, PharmD PGY2 Ambulatory Care Pharmacy Resident Kaiser Permanente Colorado June 4, 2016.

Slides:



Advertisements
Similar presentations
Hepatitis C Treatment in Corrections: New Medicine, New Challenges
Advertisements

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
By:Samia B PharmD Candidate’14 Viral Hepatitis C and Newer Pharmacologic Therapies.
Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.
HCV: Treat now or Defer Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL JUNE 19,
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1b PEARL-II.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study 3D (Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir) + RBV in GT1 TURQUOISE-I.
Hepatitis web study Hepatitis web study Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial Phase 2a Treatment Naïve and Treatment Experienced Source:
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Hepatitis web study Hepatitis web study Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Phase 2b Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.
Harvoni® ledipasvir/sofosbuvir
Hepatitis web study Hepatitis web study Simeprevir in HIV Coinfection, GT-1 C212 Trial Phase 3 Treatment Naïve and Treatment Experienced Dieterich D, et.
Hepatitis C Disease & Treatment.
Hepatitis C What’s New Alan Kilby, M.D. Portland Gastroenterology Center Maine Medical Center VTC Sept 27, 2013.
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
SPRINT-2/RESPOND-2 Boceprevir Plus Standard of Care Phase 3 Clinical Trials Analysis of Resistance Associated Variants by HCV Genotype 1 subtypes 1a and.
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
Wyoming Department of Health Communicable Diseases
HEPATITIS 2014 BC. CHRONIC HEPATITIS B THE PROBLEM 350,000,000 PEOPLE HAVE IT IT IS TRANSMITTED MOTHER TO CHILD WHERE IT IS ENDEMIC IT CAN BE TRANSMITTED.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
Treatment of Chronic HCV Genotype 4
The Lancet. Infectious diseases. June 2015, PMID:
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.
A systematic review of hepatitis C clinical practice guidelines: Benefits, limitations and harms Lim, D., Siegel, E., Hepworth, J., Bain, T., and van Driel,
OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
Hepatitis C The Silent Epidemic
SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.
SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.
Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
Hepatitis C. Overview Introduction & Facts about Hepatitis C HCV Infection & Complications Genotypes & Treatment Medications Outcomes Follow up.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology Duke University School of Medicine Durham, North Carolina Treatment of Hepatitis C in Patients.
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
به نام خداوند بخشنده مهربان. Treatment of HIV/HCV & HIV/HBV coinfection Dr. Davoudi Infectious diseases specialist Antimicrobial research center Mazandaran.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 4 Robert G. Gish MD Staff Physician, (Consultant) Stanford.
HCV Update: 18 July 2016 Ardis Ann Moe, M.D.
Epclusa® sofosbuvir/velpatasvir
New HCV reimbursement criteria
The changing landscape of hepatitis infection
Treatment Outcomes for Chronic Hepatitis C Infection with Direct Acting Antivirals among Inmates in Federal Corrections Smith JM, Boudreau H, Kom E, Tremblay.
Phase 3b Treatment-Naive
Phase 3 Treatment-Naïve and Treatment-Experienced
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1b TURQUOISE-III
Sofosbuvir and Ledipasvir Combination with and without Ribavirin in Patients with Hepatitis C Virus Infection; Preliminary Report of an Experience from.
Sofosbuvir plus Peg-Interferon and Ribavirin in Treatment Experienced Patients with Hepatitis C Virus and HIV Co-Infection Mehri Nikbin, MD Infectious.
Resistance to HCV direct-acting antivirals: What should we know?
Guangdi Li, Erik De Clercq
Hepatitis Tutoring Part 2
Update on Hepatitis C and New Treatment Options
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Case 53-year-old Black Man
Simeprevir in HIV Coinfection, GT-1 C212 Trial
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir Prof.dr.Abdel fattah hanno Dr. Doaa al wazzan.
Volume 68, Issue 4, Pages (April 2018)
Phase 3 Treatment-Naïve and Treatment-Experienced
Presentation transcript:

Updates in the Treatment of Hepatitis C Kelsey Palmer, PharmD PGY2 Ambulatory Care Pharmacy Resident Kaiser Permanente Colorado June 4, 2016

Disclosures I have no conflicts of interest or financial sponsorship to disclose

Learning Objectives Understand the prevalence and pathophysiology of hepatitis C Compare and contrast both past and current treatments for hepatitis C Review new therapies for hepatitis C, including those for less common genotypes

Patient Case MP is a 38 year-old male with hepatitis C. He’s reported no symptoms but was tested based on his former IV drug use. He has not used drugs for nearly 2 years. He is told he has genotype 1. Medications: Citalopram 20 mg/day Lisinopril 5 mg/day Significant past medical history: Depression Hypertension Allergies None

Prevalence of Hepatitis C Approximately 3 million individuals in the US are infected with hepatitis C 170 individuals infected worldwide Likely greater based on potential undiagnosed cases Becomes chronic in approximately 75-85% of cases

Pathophysiology Spherical, enveloped, single-stranded RNA virus Targets hepatocytes Viremia persists in majority of infected individuals Varying degrees of hepatic fibrosis and inflammation Pawlotsky JM. Trends Microbiol

Acute vs. Chronic Acute Short-term viral infection Some individuals may not experience symptoms Infectious only for small window of time If symptoms do present, typically mild and include fatigue and vomiting Disease resolves without treatment Acute Short-term viral infection Some individuals may not experience symptoms Infectious only for small window of time If symptoms do present, typically mild and include fatigue and vomiting Disease resolves without treatment Chronic Disease does not improve or resolve May lead to long-term problems including liver damage or cancer Chronic Disease does not improve or resolve May lead to long-term problems including liver damage or cancer

Hepatitis C Genotypes Genotype- classification of the virus based on genetic material May be broken down further into subtypes Genotype 1a, 1b Genotype 2a, 2b, 2c, 2d Genotype 3a, 3b, 3c, 3d, 3e, 3f Genotype 4a 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j Genotype 5a Genotype 6a reviews/genotypes.asp

Hepatitis C Genotypes Genotype 1 is the most common Approximately 75% of cases are genotype 1 (a or b) Approximately 25% have genotypes 2 or 3 Helpful to know genotype for treatment recommendations Duration of therapy differs based on genotype Different areas of the world have different distributions of genotypes

Symptoms of Hepatitis C Majority of people (70-80%) do not experience symptoms If symptoms do arise, they are generally mild/flu-like: Fatigue Muscle pain Poor appetite Nausea/vomiting Fever Itchy skin Dark urine Jaundice Hepc.liverfoundation.org

Who Should be Treated? Recommended for all patients with chronic hepatitis C, excluding those with short life-expectancies from co- morbid conditions Immediate treatment is assigned the highest priority, which includes patients with: Advanced fibrosis Compensated cirrhosis Liver transplant recipients Severe extrahepatic hepatitis C High risk of transmission Hepatitis C Online

Treatment Controversy Newer, highly effective oral agents prevent overutilization of healthcare resources May prevent transplant/complications down the road Upwards of 95% cure rate Many of these medications have been dubbed “$1000-a-day pills” Only a small number of patients with hepatitis C go on to develop cirrhosis No way to identify which patients with hepatitis C will progress to severe liver disease Schiff L. Clin Ther

AgentDoseADRCombo UseOther RibavirinWeight Based 1000mg/day <75kg, 1200mg/day >/=75kg dependent on genotype Severe, not well tolerated 2 black box warnings: hemolytic anemia, birth defects Never as monotherapy Resistance Major drug interactions Peginterferon (PEG-IFN) 180 mcg subq once weekly Dose modifications for leukopenia, thrombocytopenia, depression, increased ALT, renal insufficiency Numerous, frequently problematic Neutropenia, thrombocytopenia, ocular symptoms Only approved in combo with ribavirin with compensated liver disease +/- direct antiretroviral No resistance issues Fewer drug interactions C/I in autoimmune hepatitis, hepatic decomposition in cirrhosis Hepatitis C Online. Ribavirin. Peginterferon.

Olysio® (simeprevir) Approved November 2013 Mechanism: NS3/4A protease inhibitor Genotypes: Originally approved for genotype 1 in combination with PEG-INF and ribavirin November approved in combination with sofosbuvir for patients with genotype 1 Never used as monotherapy May cause photosensitivity reaction Resistance can be a significant problem Simeprevir package insert

Sovaldi® (sofosbuvir) Approved December 2013 Mechanism: nucleotide analog NS5B polymerase inhibitor Genotypes: Approved for genotypes 1 and 4 for treatment-naïve adults in combo with PEG-IFN and ribavirin 1 st approved interferon-free treatment regimen for HCV genotypes 2 and 3 Well-tolerated High genetic barrier to resistance Noell BC. Drug Des Devel Ther

Harvoni® (ledipasvir/sofosbuvir) Approved October 2014 Mechanism: Ledipasvir- NS5A inhibitor Sofosbuvir- nucleotide analog NS5B polymerase inhibitor Genotypes: Originally approved for genotype 1 (treatment-naïve and experienced) November expanded for use in genotype 4,5,6 and for co-infection with HIV February expanded for use in genotype 1 who are liver transplant recipients Once-daily, uncomplicated regimen (favorable for adherence) Harvoni package insert.

Viekira Pak® (ombitasvir, paritaprevir, ritonavir, and dasabuvir) Approved December 2014 Mechanism: Ombitasvir- NS5A inhibitor Paritaprevir- NS3/4A protease inhibitor Ritonavir- CYP3A4 inhibitor Dasabuvir- NS5B polymerase inhibitor May be used with or without ribavirin Recommended to be used with ribavirin except for 1b without cirrhosis Genotypes: Approved for genotype 1 a and b, with or without cirrhosis Viekira Pak package insert.

Daklinza® (daclatasvir) Approved July 2015 Mechanism: NS5A inhibitor Genotypes: Indicated for genotype 3 (in combination) Feb expanded use (in combination) with or without ribavirin for genotypes 1 and 3 Also included co-infection, decompensated cirrhosis, or following liver transplantation Indicated for use with sofosbuvir Recommended duration of therapy is 12 weeks, although optimal duration remains unknown Daklinza package insert.

Zepatier® (elbasvir/grazoprevir) Approved January 2016 Mechanism: Elbasvir- NS5A inhibitor Grazoprevir- NS3/4A protease inhibitor Genotypes: Approved for genotypes 1 and 4 Recommended to test for polymorphisms to determine duration and addition of ribavirin Distinct from earlier generation protease inhibitors Activity against some major resistance-associated variants Zepatier package insert.

Selection of Treatment Regimen Consider the following: Genotype History of prior treatment (naïve vs. experienced) Stage of fibrosis Adverse effect profile Drug interactions Duration of therapy Cost

GenotypeRegimens- Treatment Naïve Regimens- Treatment Experienced Genotype 1 Ledipasvir-sofosbuvir Elbasvir-grazoprevir Ombitasvir-paritaprevir- ritonavir + dasabuvir ( +/- wt based ribavirin) Simeprivir + sofosbuvir Daclatasvir + sofosbuvir Prior PEG-IFN and ribavirin failure Ledipasvir-sofosbuvir Elbasvir-grazoprevir Ombitasvir-paritaprevir- ritonavir + dasabuvir Simeprevir + sofosbuvir Daclatasvir + sofosbuvir Prior protease inhibitor failure Ledipasvir-sofosbuvir Daclatasvir + sofosbuvir +/- wt based ribavirin

GenotypeWith cirrhosisWithout cirrhosis Genotype 2Sofosbuvir + wt based ribavirin (12 weeks) Daclatasvir + sofosbuvir if contraindication to ribavirin (12 weeks) Sofosbuvir + wt based ribavirin (16 weeks) Daclatasvir + sofosbuvir if contraindication to ribavirin (24 weeks) Genotype 3Daclatasvir + sofosbuvir + wt based ribavirin (24 weeks) Other options less preferable as they are longer duration, include interferon, more expensive, not well studied Daclatasvir + sofosbuvir (12 weeks)

GenotypeRecommended Therapies Genotype 4Ledipasvir-sofosbuvir (12 weeks, regardless of cirrhosis or previous failure) Elbasvir-grazoprevir (+ wt based ribavirin if treatment experienced) Ombitasvir-paritaprevir-ritonavir + ribavirin Sofosbuvir + ribavirin Genotype 5Ledipasvir-sofosbuvir (12 weeks) Sofosbuvir + PEG-IFN + ribavirin (12 weeks) Genotype 6Ledipasvir-sofosbuvir (12 weeks) Sofosbuvir + PEG-IFN + ribavirin (12 weeks)

Back to MP…. What additional information do you want to know? Drinks alcohol, but no cirrhosis Minimal liver fibrosis Has not previously tried/failed other therapies Treatment is not cost-prohibitive for him Does not have renal disease His viral load is >6 million international units/mL

Back to MP… What treatment option would you chose for MP? A) Daclatasvir + sofosbuvir + wt based ribavirin GREEN B) Ledipasvir-sofosbuvir PINK C) Simeprevir PURPLE D) Ombitasvir-paritaprevir-ritonavir plus dasabuvir YELLOW

Back to MP… You decide to use ledipasvir-sofosbuvir to treat MP Do you want to use in combination with ribavirin? A) Yes GREEN B) No PINK How long should he be treated for? A) 8 weeks GREEN B) 12 weeks PINK C) 24 weeks PURPLE D) 48 weeks YELLOW

Questions? Contact: Kelsey Palmer, PharmD PGY2 Ambulatory Care Pharmacy Resident